Key result
Inflammatory and hemodynamic biomarkers enhance cardiovascular risk stratification in resistant hypertension.
Why the study?
Traditional risk assessment scales do not adequately account for specific factors associated with resistant arterial hypertension, including systemic inflammation and hemodynamic overload, complicating risk stratification and treatment personalization.
Incorporating inflammatory (IL-6, hs-CRP) and hemodynamic (NT-proBNP) biomarkers into clinical practice could improve cardiovascular risk stratification and personalized therapy for patients with resistant arterial hypertension.
Answers are grounded in this paper and cite their sources.
May support refined risk stratification in resistant hypertension; leaves open prospective validation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shukurova et al. (2026) conducted a review in Resistant arterial hypertension. Inflammation (hs-CRP, IL-6) and hemodynamic overload (NT-proBNP) biomarkers vs. Routine clinical evaluation without specific biomarker profiling was evaluated. Biomarkers of systemic inflammation (hs-CRP, IL-6) and hemodynamic overload (NT-proBNP) enable more accurate cardiovascular risk stratification and phenotypic profiling in resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: